Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients with Medication-Refractory, Tremor-Dominant Parkinson Disease
JAMA Neurol 74:1412-1418, Bond, A.E.,et al, 2017
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Tremor
JAMA 311:948-954, Elias, W.J. & Shah, B.B., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Deep Brain Stimulation
JAMA 305:732, Pluta,R.,et al, 2011
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Practice Parameter: Treatment of Nonmotor Symptoms of Parkinson Disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:924-931, Zesiewicz,T.A.,et al, 2010
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Deep Brain Stimulation
Neurologist 13:237-252, Kem,DS. &Kumar,R., 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Camptocormia
Neurol 65:355-359, Azher,S.N. &Jankovic,J., 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Neuroprotection in Parkinson Disease, Mysteries, Myths, and Misconceptions
JAMA 291:358-364, Schapira,A.H.V.&Olanow,C.W., 2004
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Parkinson's Disease
Lancet 363:1783-1793, Samii,A.,et al, 2004
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Acupuncture in Clinical Neurology
The Neurologist 9:137-148, Rabinstein,A.A. &Shulman,L.M., 2003
Five-Year Follow-up of Bilateral Stimulatioin of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 349:1925-1934,1888, Krack,P.,et al, 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002
DBS and Diathermy Interaction Induces Severe CNS Damage
Neurol 56:1384-1386, Nutt,J.G.,et al, 2001
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Surgery for Parkinson Disease
Arch Neurol 57:1118-1125, Lang,A.E., 2000